Archived explainer. For the current picture see today's ALNY page.
ALNYLAM PHARMACEUTIC (ALNY) is down -5.54% in the latest session. Our newswire has captured 1 story on ALNY across 1 source in the last 36 hours, with AI sentiment reading bearish (avg 34/100).
ALNY stock fell 5.54% to $267.47 in a session marked by a broader reaction to a major Phase 3 trial failure in the biotech sector. The decline came as investors digested the news that Wainua missed its Phase 3 endpoint, which disproportionately hurt Ionis Pharmaceuticals while benefiting rivals such as AstraZeneca, BridgeBio, and Alnylam Pharmaceuticals. The stock’s move reflects shifting sentiment in the sector and a reevaluation of relative risk exposure.
The failure of Wainua’s Phase 3 trial triggered a reallocation of investor capital within the biotech space. Alnylam Pharmaceuticals, which had previously faced scrutiny for its own late-stage development risks, saw its stock fall as the broader market recalibrated. The decline in ALNY came despite the company’s strong fundamentals, including a trailing twelve-month revenue growth of 82.6% and a net margin of 12.5%. A single insider transaction was reported on June 1, when David E. Pyott, a director, sold shares. The broader market response was amplified by the fact that AstraZeneca was able to absorb the blow of Wainua’s failure more easily, shifting capital to perceived safer or more promising alternatives.
ALNY traded near its 52-week low of $266.43, indicating a sharp correction from its recent performance. The stock’s beta of 0.27 suggests it is less volatile than the broader market, yet it has seen a significant drop in sentiment, with its 7-day average falling to 49 out of 100 from a 30-day average of 60. Over the past 90 days, insiders sold $1.1 million worth of shares, with no buy transactions reported. Meanwhile, recent congressional trades by Donald J. Trump included both purchases and sales in the $1,001, $15,000 range, with the most recent sale disclosed on July 1.
The stock is currently trading near its 52-week low and will be closely watched for signs of stabilization. No earnings date was provided in the data, but coverage breadth and insider activity will remain key indicators for near-term direction.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
More on ALNY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALNY move explainers: 2026-07-20 · 2026-07-17